Summit Therapeutics Share Discussion Threads

[chrisatrdg] 02/11/2017 21:11

Summit tweet today:

Summit Therapeutics‏ @Summitplc

November is #Cdiff awareness month. We'll B joining @cdifffoundation at their conference next week 2 discuss potential of ridinilazole 4 CDI
1 reply 4 retweets 2 likes

[waterloo01] 02/11/2017 19:32

Unless something has leaked into the market, in which case we would have an RNS tomorrow, I can't quite see what this is about. They took short term money issues off the table with the raise and and the Barda funding was not long ago.

[football] 02/11/2017 19:20

Same here waterloo01 whenever I buy a stock it tanks and if I sell it's like it's on rocket fuel for the next week or so

[waterloo01] 02/11/2017 19:01

My timing for buying is proving rather off!

[freemoney2] 02/11/2017 16:43

I agree, but I think the market have seen enough research and theory now. The key will be proof of concept in the boys to attribute really value to the stock. Until then the share price will trade on sentiment I guess.

Also maybe until 2020/21 when we know our C.Diff drug will hit the market in a very big way!

[waterloo01] 02/11/2017 16:11

Freemoney, yes the 'in man/boy' is the trial, but the research helps give a better understanding of how it works (in mice and hopefully men/boys).

[freemoney2] 02/11/2017 15:59

It is only mice, not men.
I guess the market is just waiting for Phaseout patient trial for proper proof of concept. Hopefully in Q1, but we may have to wait for the full 48 week results in Q3. Everything crossed for the patients and the science, but we cannot control the markets and share price... that's a whole different problem. GLA

[waterloo01] 02/11/2017 15:25

Surprised by lack of comment on the above research. Looks like good news in a further validation. Why don't Summit tweet it?

[waterloo01] 01/11/2017 15:53

I've been doing some digging and have found a recent paper, published on the 24th Oct, that looks encouraging. Research funded by Medical research council and DMD groups,

Excellent to see some further evidence (in mice) that Utrophin upregulation might just work!




Conclusions

Here, we show that utrophin over-expression in dystrophic muscle improves mitochondrial structure/localisation and reduces oxidative stress and that these benefits are potentially due to improved membrane integrity. We also show a detrimental impact on these parameters in dko mice, emphasising the importance of utrophin. Our results highlight the effectiveness of utrophin in alleviating mitochondrial pathology resulting from dystrophin deficiency. Additionally, we demonstrate the antioxidant effect of utrophin modulation, further elucidating its molecular impact on dystrophic muscle and relevance in multi-faceted treatment approaches for DMD patients.

Edit: I've added a few, although not back to my original holding, but really don't think it should be trading below $12.00 but Nasdaq heading the other way!

[hugus maximus] 01/11/2017 15:14

IMO Chris ... gene editing for DMD is still some way off and it's misunderstanding of Summit's work by lemming investors and general sentiment at play with the Summit share price Certainly nothing to do with the science.

Nothing's changed here over the past few weeks with Summit's work ... there's been no bad news. However until DMD P2 results due in Q1 2018, there's not much for the market to buy into. (Though final C Diff funding might still encourage some folk to return if that news is first) As C Diff success continues toward P3, that underpins everything here anyway.

IMHO Sarepta's DMD therapy Exondys 51 (in that article) was approved with the FDA under very bizarre circumstances due to the small sample of patients and lack of placebo. Whilst that article discusses current "success" with it's potential 13% of boys, (not 100% due to genetic limitations) Sarepta still haven't produced a decent P2 proof of concept for that drug until results due in early 2019 say otherwise .... all of which needs putting in place before they advance their treatment toward a cure for 100% of DMD boys.

For anyone new here ... Summit's DMD drug was designed to work with 100% from the start. If in Q1 2018 SMTC1100 (particularly the F6 formulation) is shown to have some benefit for the boys, the lemmings will be back for good.

[chrisatrdg] 01/11/2017 12:54

Is the following another reason for the continual downfall in Summits share price on both sides of the Atlantic justified or not:

Sarepta turns to Duke’s CRISPR work for next-gen DMD therapies

[chrisatrdg] 27/10/2017 19:54

Hi waterloo01 These current low SP's are tempting for me I am maxed out but looks like others have also bought in but good to see your further committed.Regards.

[waterloo01] 27/10/2017 17:28

Well I bought a few yesterday.

[chrisatrdg] 27/10/2017 15:40

NASDAQ is up 2.65%

At present NASDAQ is up 2.65% at $10.07 hopefully it will remain at this level or more.Read many of the posts & agree with most of whats been said & it is now a long journey back to where we were a few weeks back.I am hoping that publication of the 3rd Qtrs accounts late November or early December will be a further opportunity for further positive updates & a boost to the share price The only consolation is that the science remains sound it is the ever increasing extension of time lines that is frustrating both investors & the share price

[wooster4] 26/10/2017 14:28

Artrade - i find what my wife doesn't know can't hurt her!!!

[artrade] 26/10/2017 13:07

Wooster4, I agree there is no risk for the option holders and I have mentioned a number of times over the years the lack of concern and small shareholder directed incompetence of the board and frustration with the delays. My point was that they at least have more to gain by a rise in share price if you own more sharesIt was clear to me as soon as the recent placing was made that it was the same old summit and I'm down £50k in one month. Wife not best pleased..

[tilly99] 25/10/2017 22:20

Glyn Glyn the option man Rewarded with options at all time low prices for failure Wow he's got millions of options at v low prices cos he's places shares at deep discounts with mates You couldn't make it up!!

[chrisatrdg] 25/10/2017 22:07

PTC update link to letter:

[wildbunch] 25/10/2017 19:28

You could not make it up. The share price plummets and there is an RNS allocating yet more options to the CEO and Chairman-dependent on unspecified corporate objectives. What is wrong with them and the CFO also buying a shedload at rock bottom prices. About time bonuses have to be taken in shares which must be held for a minimum of say two or three years.

[waterloo01] 25/10/2017 17:36

Now there is a surprise (not) PCTC, Atalurin rejected by FDA. Has (for now) qualified approval in EU.

Saying needs to clearly demonstrate effectiveness.

[wooster4] 25/10/2017 15:52

artrade - how is it positive that they are taking up more shares. This is a grant of options - there is absolutely no risk whatsoever to the holder. If the price goes above 180 great, if not, they've lost nothing. The fact that there are no performance targets attached says it all.

[artrade] 25/10/2017 15:12

Par for the course with summit Can been seen as positive that directors are taking up more shares but more dilution and bad timings as often the caseThe science and progress is steady though

[tilly99] 25/10/2017 14:28

More share options awarded!!Glyn loading up!!No wonder we are at multi year lows!!Shares probably rally now his price on options been set!!Glyn v lucky man!!

[tightfist] 25/10/2017 13:27

Delayed (Buy) trade reports this morning to try and spook us out!